Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells

Blood Cells, Molecules, and Diseases

Volumn 31, Issue 1, 2003, Pages 11-17

  Kawauchi, Kiyotaka ^a   Ogasawara, Toshie ^a   Yasuyama, Masako ^a   Ohkawa, Shin Ichiro ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Akt kinase; BCR ABL; CML; STI571

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA INTERFERON; CASPASE 3; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ONCOPROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 0037715079     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-9796(03)00070-6     Document Type: Article

References (26)

1. Deininger M.W.N., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood. 96:2000;3343-3356.
2. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247:1990;824-830.
3. Elephanty A.G., Hariharan I.K., Cory S. Bcr-abl, the hallmark of chronic myeloid leukemia in man, induces multple haematopoietic neoplasms in mice. EMBO J. 9:1990;1069-1078.
4. Ravandi F., Talpaz M., Kantarjian H., Estrov Z. Cellular signalling pathways new targets in leukemia therapy . Br. J. Haematol. 116:2002;57-77.
5. Lu Y., Jamieson L., Brasier A.R., Fields A.P. NF-kappaB/RelA transactivation is required for atypical protein kinase Ciota-mediated cell survival. Oncogene. 20:2001;4777-4792.
6. Sonoyama J., Matumura I., Ezoe S., Satoh Y., Zhang X., Kataoka Y., Takai E., Mizuki M., Machii T., Wakao H., Kanakura Y. Functional cooperation among ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J. Biol. Chem. 277:2002;8076-8082.
7. Ehrhardt A., Ehrhardt G.R.A., Guo X., Schrader J.W. Ras and relatives-job sharing and networking keep an old family together. Exp. Hematol. 30:2002;1089-1106.
8. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature. 410:2001;37-40.
9. Kang C.-D., Yoo S.-D., H B.-W., Kim K.-W., Kim D.-W., Kim C.-M., Kim S.-H., Chung B.-S. The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells. Leuk. Res. 24:2000;527-534.
10. Yamaguchi H., Wang H.-G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene. 20:2001;7779-7786.
11. Abraham R.T. Identification of TOR signaling complexes more TORC for the cell growth engine . Cell. 111:2002;9-12.
12. Skorski T., Bellacosa A., Nieborowska-Skorska M., Majewski M., Martinez R., Choi J.K., Trotta R., Wlodarski P., Perrotti D., Chan T.O., Wasik M.A., Tsichlis P.N., Calabretta B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16:1997;6151-6161.
13. Talpaz M. Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. Semin. Hematol. 38:(Suppl.):2001;22-27.
14. Mauro M.J., O'Dwyer M., Heinrich M.C., Druker B.J. STI571 a paradigm of new agents for cancer therapeutics . J. Clin. Oncol. 20:2001;325-334.
15. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmerman J., Lydon N.B. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat. Med. 2:1996;561-566.
16. Tauchi T., Yoshimura A., Ohyashiki K. CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation involvement of the ubiquitin proteasome pathway . Exp. Hematol. 29:2001;356-361.
17. Klejman A., Rushen L., Morrione A., Slupianek A., Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene. 21:2002;5868-5876.
18. Kawauchi K., Ogasawara T., Yasuyama M. Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia. Int. J. Hematol. 75:2002;508-513.
19. T. Ogasawara, M. Yasuyama, K. Kawauchi, Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders. Int. J. Hematol. (2003) in press.
20. Dan S., Naito M., Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP57148. Cell Death Differ. 5:1998;710-715.
21. Klucher K.M., Lopez D.V., Daley G.O. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood. 91:1998;3927-3934.
22. Yu C., Krystal G., Varticovksi L., McKinstry R., Rahmani M., Dent P., Grant S. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res. 62:2002;188-199.
23. Nimmanapalli R., O'Bryan E., Bhalla K. Geldanamycin and its analog 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human blasts. Cancer Res. 61:2001;1799-1804.
24. Vigneri P., Wang J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat. Med. 7:2001;228-234.
25. Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., Baldwin A.S. A requirement for NF-κB activation in BCR-ABL-mediated transformation. Genes Dev. 12:1998;968-981.
26. Yu C., Geoffrey K., Dent P., Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin. Cancer Res. 8:2002;2976-2984.